Advanced therapy medicinal products (ATMPs), including cell and gene therapies (CGTs), have the potential for transformational health gains beyond our traditional pharmacological armamentarium, but the challenges of developing the optimal evidence package and payer value proposition are significant.

Developers of CGT therapies must navigate complex issues throughout clinical development, including the
most intricate clinical value chain in modern medicine, long and nonlinear patient journeys, and efficacy and
safety questions requiring many years of study.